{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032503","form_type":"8-K","ticker":"IDXG","cik":"0001054102","company_name":"INTERPACE BIOSCIENCES, INC.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.437298+00:00","generated_at":"2026-06-21T18:01:17.087885+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Interpace stockholders approve equity plan share increases and reverse split authorization","bullets":["Stockholders approved amendment to 2019 Equity Incentive Plan, increasing authorized shares by 1,000,000 to total 2,230,000.","Stockholders approved amendment to Employee Stock Purchase Plan, increasing authorized shares by 1,000,000 to total 2,000,000.","Stockholders granted board discretionary authority to effect a reverse stock split within range of 1-for-2 to 1-for-10, within one year.","Stephen J. Sullivan elected as Class I director, receiving 8,793,313 votes for and 820,085 withhold.","Ratification of EisnerAmper LLP as independent auditor for fiscal year ending Dec 31, 2022 approved with 11,041,434 votes for."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032503","json":"https://secwatch.observer/filing/0001493152-22-032503.json","markdown":"https://secwatch.observer/filing/0001493152-22-032503.md","text":"https://secwatch.observer/filing/0001493152-22-032503.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T18:01:17.087885+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1308909299b2759224a12ffb07d6bfca5d95e7f5","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the ESPP Amendment. at the 2022-11-10 meeting.","evidence_excerpt":"III. Approval of the ESPP Amendment. For Against Abstain Broker Non-Votes 9,501,243 85,297 26,858 1,522,847","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-10"}],"fact_type":"shareholder_vote"},{"claim_id":"22704fda5809dfe8419bcec6176828948cbb4ca6","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. at the 2022-11-10 meeting.","evidence_excerpt":"V. Ratification of the appointment of EisnerAmper, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. For Against Abstain Broker Non-Votes 11,041,434 35,207 59,604 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-10"}],"fact_type":"shareholder_vote"},{"claim_id":"4505caa2eeeb41f9abed743432e30e04df28808d","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Approval of the Plan Amendment. at the 2022-11-10 meeting.","evidence_excerpt":"II. Approval of the Plan Amendment. For Against Abstain Broker Non-Votes 9,498,523 88,097 26,778 1,522,847","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-10"}],"fact_type":"shareholder_vote"},{"claim_id":"c62c35bc3a85cc18c46e5b82ef7f496b72b2095b","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved Election of one Class I director to serve until the 2025 annual meeting or until such director's successor is duly elected and qualified. at the 2022-11-10 meeting.","evidence_excerpt":"I. Election of one Class I director to serve until the 2025 annual meeting or until such director’s successor is duly elected and qualified. Name For Withhold Broker Non-Votes Stephen J. Sullivan 8,793,313 820,085 1,522,847","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-10"}],"fact_type":"shareholder_vote"},{"claim_id":"fc293b727a9aad5682a120d4008979949b5dac36","claim":"INTERPACE BIOSCIENCES, INC. shareholders approved To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Boar at the 2022-11-10 meeting.","evidence_excerpt":"IV. To grant the board of directors of the Company (the “Board”) discretionary authority to amend the Company’s Certificate of Incorporation, as amended, to effect a reverse stock split of its common stock within the range of 1-for-2 to 1-for-10 with the exact ratio, if any, to be determined by the Board, but not later than one year after stockholder approval thereof. For Against Abstain Broker Non-Votes 10,270,993 800,853 64,399 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1054102/000149315222032503/0001493152-22-032503-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2022-11-10"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}